X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020
X4 Pharmaceuticals (Nasdaq: XFOR) will announce its third-quarter financial results on November 5, 2020. The company will provide updates on its business highlights during a conference call at 8:30 a.m. ET, accessible through U.S. and international dial-ins. X4 focuses on developing therapies targeting the CXCR4 pathway, with its lead candidate mavorixafor undergoing Phase 3 trials for WHIM syndrome and Phase 1b trials for other conditions. Interested parties can access the live webcast on the company’s investor relations page.
- Upcoming financial results announcement on November 5, 2020.
- Lead candidate mavorixafor in Phase 3 clinical trial for WHIM syndrome.
- None.
BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the third quarter ended September 30, 2020, and provide an update on recent business highlights, on November 5, 2020.
The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 1096977. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates. For more information, please visit www.x4pharma.com.
Investors and Media:
Candice Ellis, 857-341-1043
Director, Corporate Communications & Investor Relations
Candice.Ellis@x4pharma.com
FAQ
When will X4 Pharmaceuticals report its financial results?
What is the focus of X4 Pharmaceuticals?
What clinical trials is mavorixafor involved in?
What time will the X4 Pharmaceuticals conference call start?
How can I access the X4 Pharmaceuticals conference call?
